Linked Life Data

7637869

Source:http://linkedlifedata.com/resource/pubmed/id/7637869

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1995-9-11
pubmed:abstractText
The effect of a unilateral 6-hydroxydopamine lesion of the medial forebrain bundle in rats and subsequent L-DOPA treatment for eight weeks on preproenkephalin, preprotachykinin and glutamate decarboxylase (M(r) 67,000) gene expression in the striatum was investigated by in situ hybridization. A 6-hydroxydopamine lesion of the medial forebrain bundle markedly increased the level of preproenkephalin messenger RNA (+66%) and modestly elevated the level of glutamate decarboxylase (M(r) 67,000) messenger RNA (+36%) in the denervated striatum, but caused a decrease in the level of preprotachykinin messenger RNA (-54%) relative to the intact striatum and to sham-lesioned control animals. Treatment with L-DOPA (200 mg/kg/24 h) for eight weeks reduced but did not abolish the 6-hydroxydopamine lesion-induced elevation of preproenkephalin messenger RNA and slightly reduced the elevation of glutamate decarboxylase (M(r) 67,000) messenger RNA in denervated striatum relative to intact side and control groups. However, L-DOPA treatment almost completely reversed the decrease in preprotachykinin messenger RNA caused by 6-hydroxydopamine lesioning when compared to intact side and control groups. The effect of L-DOPA on the gene expression of preproenkephalin and glutamate decarboxylase (M(r) 67,000) differs from the increase in striatal enkephalin content and glutamate decarboxylase activity previously found following L-DOPA treatment. In contrast, L-DOPA reversed the changes in preprotachykinin messenger RNA, reflecting previously reported increases in substance P content. The findings provide new evidence that chronic L-DOPA treatment differentially affects direct striatonigral and indirect striatopallidal pathways at the molecular level.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0306-4522
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
19-28
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7637869-Animals, pubmed-meshheading:7637869-Base Sequence, pubmed-meshheading:7637869-Behavior, Animal, pubmed-meshheading:7637869-Carbidopa, pubmed-meshheading:7637869-Enkephalins, pubmed-meshheading:7637869-Female, pubmed-meshheading:7637869-Gene Expression Regulation, Enzymologic, pubmed-meshheading:7637869-Glutamate Decarboxylase, pubmed-meshheading:7637869-In Situ Hybridization, pubmed-meshheading:7637869-Levodopa, pubmed-meshheading:7637869-Molecular Sequence Data, pubmed-meshheading:7637869-Neostriatum, pubmed-meshheading:7637869-Oligonucleotide Probes, pubmed-meshheading:7637869-Oxidopamine, pubmed-meshheading:7637869-Protein Precursors, pubmed-meshheading:7637869-RNA, Messenger, pubmed-meshheading:7637869-Rats, pubmed-meshheading:7637869-Rats, Wistar, pubmed-meshheading:7637869-Tachykinins
pubmed:year
1995
pubmed:articleTitle
Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat.
pubmed:affiliation
Neurodegenerative Diseases Research Centre, King's College, London, U.K.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't